Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: Week 52 Results From a Phase 3b, Randomized, Double-Blind, Placebo-Controlled Trial

By sjmartinez • December 26, 2024

Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: Week 52 Results From a Phase 3b, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Acad Dermatol. 2024 Dec 23:S0190-9622(24)03393-0. doi: 10.1016/j.jaad.2024.12.018. Epub ahead of print. PMID: 39722400.

Tags: Dermatology, efficacy, itch, Olive View DoM, psoriasis, Publications, safety, scalp, tildrakizumab

Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of[...]

Upadacitinib for Alopecia: Current Evidence and Clinical Insights

Stirrat T, Thakker S, Bejugam D, Goh C, Lipner SR. Upadacitinib for Alopecia: Current Evidence and Clinical Insights. Skin Appendage Disord. 2025 Aug;11(4):320-334. doi: 10.1159/000544868.[...]

Hot Topics: Exploring Artificial Intelligence and Inflammatory Memory in the Management of Psoriatic Diseases

Shucheng H, Armstrong AW, Eidsmo L, Poddubnyy D. Hot Topics: Exploring Artificial Intelligence and Inflammatory Memory in the Management of Psoriatic Diseases. J Rheumatol. 2025[...]